Calleja, Jose L <br/><br/>
Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.  [electronic resource] 

 -  Liver international : official journal of the International Association for the Study of the Liver  Jan 2015 
 - 90-100 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1478-3231 
<br/><br/><label>Standard No.: </label>10.1111/liv.12656  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Compassionate Use Trials<br/>Drug Therapy, Combination--adverse effects<br/>Hepacivirus--genetics<br/>Hepatitis C--complications<br/>Humans<br/>Interferon-alpha--adverse effects<br/>Liver Cirrhosis--drug therapy<br/>Male<br/>Middle Aged<br/>Polyethylene Glycols--adverse effects<br/>Proline--adverse effects<br/>Prospective Studies<br/>Protease Inhibitors--adverse effects<br/>Recombinant Proteins--adverse effects<br/>Ribavirin--adverse effects<br/>Spain